MétaCan
Menu
Back to cohort
Record W4416705587 · doi:10.1055/s-0043-1777199

A Phase 1 Study to Assess the Effect of Food on the Pharmacokinetics (PK) and Gastrointestinal (GI) Tolerability of Selumetinib in Adolescents with Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PN)

2023· article· en· W4416705587 on OpenAlexaff
Mariusz Wysocki, Maria Learoyd, Peng Sun, Karen So, Andrew Evans, Fancai Lai, David Viskochil

Bibliographic record

VenueNeuropediatrics · 2023
Typearticle
Languageen
FieldMedicine
TopicNeurofibromatosis and Schwannoma Cases
Canadian institutionsAstraZeneca (Canada)
Fundersnot available
KeywordsNeurofibromatosisSelumetinibTolerabilityPharmacokineticsNeurofibromatosis type I

Abstract

fetched live from OpenAlex

Background/Purpose: Selumetinib is a MEK1/2 inhibitor approved for pediatric patients with NF1 and symptomatic, inoperable PN in regions including EU (EMA, aged ≥3 years). The aim of this study was to evaluate the effect of a low-fat meal on steady-state exposure and GI tolerability in adolescents with NF1 and inoperable PN to confirm a recommendation for dosing selumetinib with food by a Ph 1 study (NCT05101148). Methods: Eligible patients aged ≥12 to <18 years received selumetinib 25 mg/m 2 two times daily for one cycle (28 days) with a low-fat meal according to FDA guidance (T1; fed C1), then in a fasted state for one cycle (T2; fasted C1) following 1-week washout. T2 continued beyond one cycle until the end of the study or dose-adjusted selumetinib in a fed state (T3), if required. 1° endpoints were AUC 0–12,ss , GI adverse events (AEs; CTCAE v5.0), and GI concomitant medications in fed versus fasted state. 2° endpoints included other PK parameters and safety. Results: Twenty-four participants received selumetinib; 19 were evaluable for fed versus fasted paired PK comparison. Mean duration of exposure for fed and fasted states was 28.3 (SD 1.1) and 28.3 (SD 3.0) days, respectively. Steady-state extent of absorption was similar for fed versus fasted (AUC 0–12,ss geometric mean ratio [GMR] 0.919; lower one-sided 90% CI bound 0.841). Fed-state C max was reduced (GMR 0.763; lower 1-sided 90% CI bound 0.667) and time to C max was delayed (34 minutes; 90% CI 28, 60; Figure 1) versus fasted state. Similar number of subjects experienced GI AEs (fed C1, 29.2%; fasted C1, 33.3%). GI PROs were consistent between fed C1 versus fasted C1. Overall use of concomitant GI medications was low. No new safety signals were identified. Conclusion: At steady state, dosing selumetinib with a low-fat meal delayed absorption rate and lowered C max but had no clinically significant effect (<30% AUC 0–12,ss reduction) on extent of absorption and GI tolerability. Thus, dose adjustment is unlikely required. This study shows dosing selumetinib with a low-fat meal has no significant impact on AUC or GI tolerability. Publication History Article published online: 13 November 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.003
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.037
GPT teacher head0.305
Teacher spread0.268 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractno

Explore more

Same venueNeuropediatricsSame topicNeurofibromatosis and Schwannoma CasesFrench-language works237,207